Accessibility Menu
Lineage Cell Therapeutics logo

Lineage Cell Therapeutics(NYSEMKT) LCTX

Market Cap$269.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-63%
5 Year-59%
1 Year+6%
1 Month-17%
$1.09
-2.25%
-0.02Today
Lineage Cell Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.082026-07-31
Lineage Cell Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.85%USD 1.032026-07-24
1 month-16.92%USD 1.302026-07-01
3 month-29.41%USD 1.532026-05-01
Year to date-35.33%USD 1.672025-12-31
1 year+5.88%USD 1.022025-07-31
3 year-23.94%USD 1.422023-08-01
5 year-58.94%USD 2.632021-07-30
Since inception-63.16%USD 2.931992-05-01

Lineage Cell Therapeutics Financials at a Glance

Market Cap

$269.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$14.78M

Net Income (TTM)

-$64.21M

EPS (TTM)

-$0.29

P/E Ratio

-3.76

Dividend

$0.00

Beta (Volatility)

1.13 (Average)

Price

$1.09

Volume

948,845.105

Open

$1.11

Previous Close

$1.08

Daily Range

$1.07 - $1.13

52-Week Range

$0.95 - $2.09

Estimated Earnings Date

Aug 11, 2026

LCTX News

Foolcom-Featured.png

Lineage Cell Revenue Doubles in Q2

Motley Fool Markets TeamAug 12, 2025
A medical professional using a microscope

Why Lineage Cell Therapeutics Zoomed Higher Today

Eric VolkmanDec 20, 2021
AMD

Why Lineage Cell Therapeutics Stock Is Soaring Today

Keith SpeightsJun 1, 2021
GettyImages-1168199832

Why Lineage Cell Therapeutics Stock Popped Today

Prosper Junior BakinyApr 20, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lineage Cell Therapeutics

Lineage makes new cells to fix damaged body parts. These cells help people see better or move again. The company grows replacement cells for many patients.

New Parts for the Human Body

  • OpRegen: Replacement cells for geographic atrophy, a severe form of vision loss caused by dry age-related macular degeneration.
  • OPC1: Nerve cell therapy used to repair the spine after a serious injury; aims to help patients regain movement.
  • ReSonance: Ear nerve cells designed to treat auditory neuropathy, which is a specific type of hearing loss.
  • ILT1: Research initiative focused on producing large amounts of cells for potential diabetes treatments.

Strategic Deals and Lab Wins

  • Partnered with F. Hoffmann-La Roche Ltd and Genentech in December 2021 to develop and sell the OpRegen eye therapy.
  • Agreed to a research deal with William Demant Invest 2 Aps in August 2025 to study hearing loss treatments.
  • Signed a gene-editing option with Factor Biosciences Limited in February 2023 for brain disease cell lines.
  • Launched a new initiative called ILT1 in September 2025 to solve manufacturing issues for diabetes treatments.
  • Ceased development of the VAC2 lung cancer program in June 2025, ending its collaboration with Immunomic Therapeutics.

How the Platform Works

Lineage uses its AlloSCOPE platform to grow consistent cells at a large scale for thousands of patients. It also manages its own production facility in Israel to maintain strict quality and safety standards.

Tracking the Recent Performance

  • Revenue reached $6.6 million in Q4 2025, up 130.4% from Q4 2024.
  • Net income reached $851,000 in Q4 2025, up 126% year-over-year.
  • Operating income was -$6.5 million in Q4 2025, a 28.1% worsening from Q4 2024.
  • Market capitalization grew to $384.3 million in Q4 2025, up 282% year-over-year.
  • Free cash flow hit -$5 million in Q4 2025, improving 25.7% from Q4 2024.

Scaling Science for the Future

Lineage has evolved from general research to clinical development for specific eye and nerve conditions. Its strategy relies on partnering with larger pharmaceutical firms to fund and sell its cell-replacement technology.

AI Generated • May 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

77

CEO

Brian M. Culley, MBA

Website

www.lineagecell.com

Headquarters

Carlsbad, CA 92008, US

LCTX Financials

Key Financial Metrics (TTM)

Gross Margin

97.98%

Operating Margin

-255.14%

Net Income Margin

-434.44%

Return on Equity

-152.10%

Return on Capital

-46.37%

Return on Assets

-58.62%

Earnings Yield

-26.60%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$269.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

249.30M

Volume

948.85K

Avg. Volume

1.50M

Financials (TTM)

Gross Profit

$14.48M

Operating Income

-$37.71M

EBITDA

-$43.15M

Operating Cash Flow

-$22.11M

Capital Expenditure

-$192.00K

Free Cash Flow

-$22.30M

Cash & ST Invst.

$53.38M

Total Debt

$2.39M

Lineage Cell Therapeutics Performance Analysis

Lineage Cell Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 14,703,000277.4%
20232023-12-31USD 8,945,000-39.2%
20242024-12-31USD 9,499,0006.2%
20252025-12-31USD 14,556,00053.2%
Lineage Cell Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3084.1%
Q32025-09-3033.1%
Q42025-12-3179.5%
Q12026-03-31-73.9%
Lineage Cell Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.15-40.8%
20232023-12-31USD -0.12-19.6%
20242024-12-31USD -0.09-25.2%
20252025-12-31USD -0.28196.9%
Lineage Cell Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-610.4%
Q32025-09-30N/A
Q42025-12-31102.7%
Q12026-03-31-660.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$1.73M

+14.8%

Gross Profit

$1.54M

+4.8%

Gross Margin

89.10%

N/A

Market Cap

$269.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.50M

N/A

Employees

77

N/A

Net Income

-$4.81M

-16.3%

EBITDA

-$4.60M

-15.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$53.38M

+11.4%

Total Debt

$2.39M

+6.7%

Accounts Receivable

$806.00K

+278.4%

Inventory

$0.00

N/A

Long Term Debt

$1.53M

+43.7%

Short Term Debt

$865.00K

-26.7%

Return on Assets

-58.62%

N/A

Return on Invested Capital

-37.19%

N/A

Free Cash Flow

-$8.13M

-63.2%

Operating Cash Flow

-$8.08M

-65.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GALTGalectin Therapeutics Inc.
$2.97-8.05%
FULCFulcrum Therapeutics, Inc.
$3.58-3.76%
AUTLAutolus Therapeutics plc
$1.49-2.61%
BNTCBenitec Biopharma Inc.
$11.71-1.26%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About LCTX

What is the current price of Lineage Cell Therapeutics?

Lineage Cell Therapeutics is trading at $1.08 per share.

What is the 52-week range for Lineage Cell Therapeutics?

Over the past 52 weeks, Lineage Cell Therapeutics has traded between $0.95 and $2.09.

How much debt does Lineage Cell Therapeutics have?

As of the most recent reporting period, Lineage Cell Therapeutics reported total debt of $2.39M.

How much cash does Lineage Cell Therapeutics have on hand?

Lineage Cell Therapeutics reported $35.94M in cash and cash equivalents in its most recent financial results.

What is Lineage Cell Therapeutics’s dividend yield?

Lineage Cell Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services